AVROBIO (AVRO) News Today → LEAKED: Jeff Bezos' $330 Million Gamble (From Behind the Markets) (Ad) Free AVRO Stock Alerts $1.48 +0.04 (+2.78%) (As of 05/31/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative June 1 at 2:38 PM | marketbeat.comShort Interest in AVROBIO, Inc. (NASDAQ:AVRO) Increases By 11.3%AVROBIO, Inc. (NASDAQ:AVRO - Get Free Report) was the target of a significant increase in short interest in May. As of May 15th, there was short interest totalling 181,600 shares, an increase of 11.3% from the April 30th total of 163,200 shares. Currently, 0.5% of the shares of the stock are sold short. Based on an average daily trading volume, of 219,000 shares, the days-to-cover ratio is currently 0.8 days.May 16, 2024 | insidertrades.comBraden Michael Leonard Buys 469,753 Shares of AVROBIO, Inc. (NASDAQ:AVRO) StockMay 16, 2024 | finance.yahoo.comAVROBIO, Inc. (AVRO) Stock Price, News, Quote & History - Yahoo FinanceMay 15, 2024 | fr.investing.comUn cadre d'Avrobio achète des actions d'une valeur de plus de 970 000 dollarsMay 15, 2024 | marketbeat.comInsider Buying: AVROBIO, Inc. (NASDAQ:AVRO) Major Shareholder Acquires 469,753 Shares of StockAVROBIO, Inc. (NASDAQ:AVRO - Get Free Report) major shareholder Braden Michael Leonard purchased 469,753 shares of the firm's stock in a transaction dated Monday, May 13th. The stock was purchased at an average cost of $1.25 per share, with a total value of $587,191.25. Following the acquisition, the insider now directly owns 4,471,380 shares in the company, valued at $5,589,225. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Major shareholders that own more than 10% of a company's stock are required to disclose their transactions with the SEC.May 14, 2024 | marketbeat.comShort Interest in AVROBIO, Inc. (NASDAQ:AVRO) Expands By 19.0%AVROBIO, Inc. (NASDAQ:AVRO - Get Free Report) was the recipient of a significant growth in short interest during the month of April. As of April 30th, there was short interest totalling 163,200 shares, a growth of 19.0% from the April 15th total of 137,200 shares. Based on an average daily volume of 214,200 shares, the days-to-cover ratio is currently 0.8 days. Currently, 0.4% of the company's shares are short sold.May 9, 2024 | businesswire.comAVROBIO INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Merger of AVROBIO, Inc. - AVROApril 22, 2024 | bizjournals.comDeal watch: Biopharma M&A more than doubled in Q1April 14, 2024 | marketbeat.comShort Interest in AVROBIO, Inc. (NASDAQ:AVRO) Rises By 14.6%AVROBIO, Inc. (NASDAQ:AVRO - Get Free Report) was the recipient of a significant growth in short interest in the month of March. As of March 31st, there was short interest totalling 143,200 shares, a growth of 14.6% from the March 15th total of 125,000 shares. Currently, 0.4% of the company's shares are sold short. Based on an average daily volume of 299,800 shares, the days-to-cover ratio is currently 0.5 days.March 26, 2024 | wsj.comAVROBIO Inc.March 20, 2024 | marketbeat.comAVROBIO (AVRO) Scheduled to Post Quarterly Earnings on ThursdayAVROBIO (NASDAQ:AVRO) will be releasing earnings on Thursday, March 21.March 3, 2024 | marketbeat.comAVROBIO, Inc. (NASDAQ:AVRO) Short Interest UpdateAVROBIO, Inc. (NASDAQ:AVRO - Get Free Report) saw a large drop in short interest during the month of February. As of February 15th, there was short interest totalling 126,500 shares, a drop of 30.3% from the January 31st total of 181,500 shares. Currently, 0.3% of the company's shares are short sold. Based on an average daily volume of 287,600 shares, the short-interest ratio is presently 0.4 days.March 1, 2024 | marketbeat.comAVROBIO, Inc. (NASDAQ:AVRO) Short Interest Down 30.3% in FebruaryAVROBIO, Inc. (NASDAQ:AVRO - Get Free Report) saw a large decline in short interest in February. As of February 15th, there was short interest totalling 126,500 shares, a decline of 30.3% from the January 31st total of 181,500 shares. Currently, 0.3% of the shares of the stock are short sold. Based on an average daily trading volume, of 287,600 shares, the short-interest ratio is currently 0.4 days.February 23, 2024 | ca.finance.yahoo.comAVRO Apr 2024 2.500 callFebruary 18, 2024 | finance.yahoo.comAVRO May 2024 2.500 callFebruary 14, 2024 | businesswire.comAVROBIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of AVROBIO, Inc. - AVROJanuary 31, 2024 | stockhouse.comShareholder Alert: Ademi LLP investigates whether AVROBIO, Inc. has obtained a Fair Price in its transaction with TectonicJanuary 31, 2024 | bizjournals.comFive things: Vertex's new drug, a reverse merger, and how are you doing?January 31, 2024 | msn.comAvrobio Inc Announces Executive Team Changes and AppointmentsJanuary 30, 2024 | bizjournals.comAvrobio to take Watertown biotech public via reverse mergerJanuary 30, 2024 | stockhouse.comSHAREHOLDER NOTICE: Halper Sadeh LLC Investigates AVRO, CALB, BCALJanuary 30, 2024 | msn.comAvrobio to buy 100% equity interests of Tectonic TherapeuticJanuary 30, 2024 | marketwatch.comAvrobio Shares Dive 17% After Tectonic Therapeutic DealJanuary 30, 2024 | finance.yahoo.comAVROBIO and Tectonic Therapeutic Announce MergerJanuary 30, 2024 | marketbeat.comTrading was temporarily halted for "AVRO" at 07:01 AM with a stated reason of "News pending."December 20, 2023 | benzinga.comAvrobio Stock (NASDAQ:AVRO), Analyst Ratings, Price Targets, PredictionsDecember 19, 2023 | msn.comMizuho Downgrades AVROBIO (AVRO)December 19, 2023 | benzinga.comAvrobio Stock (NASDAQ:AVRO) Dividends: History, Yield and DatesDecember 18, 2023 | realmoney.thestreet.comAvrobio just downgraded at Mizuho, here's whyNovember 14, 2023 | morningstar.comAvrobio Inc AVRONovember 14, 2023 | markets.businessinsider.comPotential Growth and Strategic Alternatives: Reasons Behind Zhu’s Buy Rating for AvrobioNovember 8, 2023 | finance.yahoo.comIs AVROBIO (AVRO) Stock Outpacing Its Medical Peers This Year?October 6, 2023 | finance.yahoo.comHas AVROBIO (AVRO) Outpaced Other Medical Stocks This Year?October 5, 2023 | msn.comAvroBio (AVRO) Price Target Increased by 12.82% to 3.74September 25, 2023 | ca.finance.yahoo.comAVROBIO, Inc. (AVRO)September 11, 2023 | benzinga.comSolu Therapeutics Appoints Philip Vickers, Ph.D., as President and Chief Executive OfficerAugust 12, 2023 | msn.comAvrobio: Net-Net Biotech Pursuing Strategic AlternativesAugust 11, 2023 | markets.businessinsider.comAvrobio (AVRO) Gets a Buy from BarclaysAugust 7, 2023 | finance.yahoo.comArbor Biotechnologies Appoints Deanna M. Petersen as Chief Business OfficerJuly 13, 2023 | nasdaq.comWells Fargo Maintains AvroBio (AVRO) Overweight RecommendationJuly 13, 2023 | finance.yahoo.comAVROBIO (AVRO) to Explore Strategic Options, Stock Rises 46%July 13, 2023 | bizjournals.comFive things you need to know today, and the Sumner Tunnel closure’s real testJuly 12, 2023 | benzinga.comWedbush Downgrades Avrobio to Neutral, Announces $2 Price TargetJuly 12, 2023 | seekingalpha.comAvrobio to explore strategic options; halts studiesJuly 12, 2023 | msn.comWhy Avrobio Shares Are Rising WednesdayJuly 12, 2023 | marketwatch.comAvrobio Shares Rise 38% After Move to Explore Strategic AlternativesJuly 12, 2023 | msn.comWedbush Downgrades AvroBio (AVRO)July 12, 2023 | bizjournals.comGene therapy startup Avrobio explores a saleJuly 12, 2023 | markets.businessinsider.comAVROBIO To Conduct Exploration Of Strategic Alternatives - Quick FactsJuly 12, 2023 | finance.yahoo.comAVROBIO to Explore Strategic Alternatives Get AVROBIO News Delivered to You Automatically Sign up to receive the latest news and ratings for AVRO and its competitors with MarketBeat's FREE daily newsletter. Email Address “This will be one of the biggest revolutions ever.” - NVIDIA CEO (Ad)NVIDIA's CEO calls it the "next amazing revolution"... The Economist says its a "boon to humanity"... And Jeff Bezos is heavily invested in it. A new breakthrough tech could add up to $20 trillion to the U.S. economy. AVRO Media Mentions By Week AVRO Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. AVRO News Sentiment▼0.920.78▲Average Medical News Sentiment AVRO News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. AVRO Articles This Week▼31▲AVRO Articles Average Week Get AVROBIO News Delivered to You Automatically Sign up to receive the latest news and ratings for AVRO and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Brainstorm Cell Therapeutics News Today Assembly Biosciences News Today vTv Therapeutics News Today Lipocine News Today LianBio News Today SAB Biotherapeutics News Today Freeline Therapeutics News Today Acasti Pharma News Today BeyondSpring News Today ZIVO Bioscience News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:AVRO) was last updated on 6/1/2024 by MarketBeat.com Staff From Our PartnersThe #1 Crypto That You Don’t Own… YetCrypto 101 MediaTrump’s Gift Could Unleash $51 Billion in New WealthWealthpin ProDems have chosen Biden replacement?Paradigm PressShocking: One AI startup's revenue could surge 4,735%Manward PressMust-See: Elon’s New Invention is Absolutely InsaneInvestorPlaceNvidia is about to pass AppleWeiss RatingsDon’t buy a single NVIDIA share before you see this...Behind the MarketsExposed: 10 CENT Crypto to Explode May 20th?True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AVROBIO, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
